Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
暂无分享,去创建一个
Patrick Neven | Sabine Van Huffel | Dirk Timmerman | Tom Bourne | Davor Jurkovic | Ben Van Calster | Lil Valentin | Caroline Van Holsbeke | D. Jurkovic | T. Bourne | B. van Calster | D. Timmerman | L. Valentin | P. Neven | S. Van Huffel | A. Testa | C. V. van Holsbeke | Antonia Carla Testa | E. Domali | Ekaterini Domali | D. Jurković | B. Van calster
[1] F. Jänicke,et al. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer]. , 1991, Gynäkologisch-Geburtshilfliche Rundschau.
[2] Y. Kitaoka,et al. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. , 2005, Human reproduction.
[3] H. Hollema,et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. , 2000, Gynecologic oncology.
[4] T. Bourne,et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[5] R. Newcombe. Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.
[6] R G Newcombe,et al. Improved confidence intervals for the difference between binomial proportions based on paired data. , 1998, Statistics in medicine.
[7] I. Timor-Tritsch,et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. , 1994, American journal of obstetrics and gynecology.
[8] R. Newcombe,et al. Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.
[9] R. Bast,et al. The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.
[10] P. Dombernowsky,et al. Tumor markers in the management of patients with ovarian cancer. , 1995, Cancer treatment reviews.
[11] Dirk Timmerman,et al. The use of mathematical models to evaluate pelvic masses; can they beat an expert operator? , 2004, Best practice & research. Clinical obstetrics & gynaecology.
[12] P. Buamah,et al. Serum CA 125 concentrations in patients with benign ovarian tumours , 1994, Journal of surgical oncology.
[13] D. Timmerman,et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[14] T. Bourne,et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Vlahos,et al. Color and Pulsed Doppler Sonography, Gray‐Scale Imaging, and Serum CA 125 in the Assessment of Adnexal Disease , 1996, Obstetrics and gynecology.
[16] P Maisonneuve,et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[17] T. Bourne,et al. Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. , 1989, BMJ.
[18] I. Vergote,et al. Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary , 1992, International Journal of Gynecologic Cancer.
[19] P. Viganò,et al. Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. , 2004, Human reproduction.
[20] P. Kenemans,et al. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. , 1993, Clinical chemistry.
[21] J. Schlaerth,et al. Serum CA 125 Levels in Preoperative Evaluation of Pelvic Masses , 1988, Obstetrics and gynecology.
[22] R. Berkowitz,et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. , 1992, Gynecologic oncology.
[23] R. Bast,et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease , 1988, American journal of obstetrics and gynecology.
[24] T. Bourne,et al. The characterization of common ovarian cysts in premenopausal women , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[25] A. Sood,et al. Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer , 2002, Obstetrics and gynecology.
[26] B. Davidson,et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. , 2000, American journal of obstetrics and gynecology.
[27] P. Kenemans,et al. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. , 1996, American journal of obstetrics and gynecology.
[28] R. Bast,et al. Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.
[29] L. Valentin. Use of morphology to characterize and manage common adnexal masses. , 2004, Best practice & research. Clinical obstetrics & gynaecology.
[30] M. Duffy,et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use , 2004, International Journal of Gynecologic Cancer.
[31] A. Gadducci,et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. , 1996, Gynecologic oncology.
[32] F. Kikkawa,et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. , 1996, Gynecologic oncology.
[33] M. Kucok. Elevated Serum CA-125 concentration in a patient with tuberculous peritonitis mimicking ovarian cancer. , 1998, The Journal of reproductive medicine.
[34] D. Oram,et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.
[35] V. Phupong,et al. High level of CA 125 due to large endometrioma. , 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[36] Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. , 1995, Gynecologic oncology.
[37] Sabine Van Huffel,et al. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] I. Jacobs,et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study , 1996, BMJ.
[39] A. Proietto,et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Kenemans,et al. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. , 1998, Clinical chemistry.
[41] Seth Granberg,et al. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation , 1990 .
[42] F. Jansen,et al. Sonographic assessment of non-malignant ovarian cysts: does sonohistology exist? , 2004, Human reproduction.
[43] R. Newcombe,et al. Confidence intervals for an effect size measure based on the Mann–Whitney statistic. Part 2: asymptotic methods and evaluation , 2006, Statistics in medicine.
[44] L. Valentin,et al. Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasound , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[45] P. Kenemans,et al. Technical evaluation of three second generation CA 125 assays. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[46] L. Valentin,et al. The role of ultrasound in the management of women with acute and chronic pelvic pain. , 2004, Best practice & research. Clinical obstetrics & gynaecology.
[47] L. Blumenson,et al. Serum CA-125 measurements > 65 U/mL. Clinical value. , 1997, The Journal of reproductive medicine.
[48] L. Valentin,et al. Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.